Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets

Area of Science:

• Medicinal Chemistry
• Biophysics
• Cellular Biology

Background:

• Traditional platinum-based chemotherapy relies on covalent DNA binding for cytotoxicity.
• Substitution-inert polynuclear platinum complexes (PPCs) present an alternative mechanism of action.
• Understanding their unique properties is crucial for developing novel anti-cancer agents.

Purpose of the Study:

• To review the chemical, biophysical, and cellular biological properties of substitution-inert PPCs.
• To elucidate their distinct DNA binding modes and cellular effects compared to covalent agents.
• To explore their potential as dual-action anti-cancer agents.

Main Methods:

• Summarized chemical, biophysical, and cellular biological data of PPCs.
• Analyzed DNA binding mechanisms, including minor groove spanning and phosphate clamp formation.
• Investigated cellular accumulation via heparan sulfate proteoglycans (HSPG) and downstream effects.

Main Results:

• PPCs bind DNA via a "phosphate clamp" mechanism, distinct from intercalation or minor groove binding.
• These complexes induce efficient nuclear condensation and exhibit cytotoxicity comparable to cisplatin.
• Cellular accumulation is mediated by HSPG, suggesting tumor selectivity and new therapeutic targets.

Conclusions:

• Substitution-inert PPCs represent a unique class of anti-cancer agents with dual-action capabilities.
• Their non-covalent DNA binding and unique cellular effects offer an alternative to traditional platinum chemotherapeutics.
• PPCs demonstrate that potent anti-cancer activity can be achieved without Pt-DNA bond formation.